Increasing dose of Continuous Infusion Ifosfamide and Fixed dose of Bolus Epirubicin in Soft Tissue Sarcomas. A Study of the Italian Group on Rare Tumors

1999 ◽  
Vol 85 (4) ◽  
pp. 229-233 ◽  
Author(s):  
Sergio Frustaci ◽  
Angela Buonadonna ◽  
Antonella Romanini ◽  
Alessandro Cornandone ◽  
Maurizio Dalla Palma ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Continuous Infusion ◽  
Soft Tissue Sarcomas ◽  
Fixed Dose ◽  
Rare Tumors

Pathologic Evaluation of Soft Tissue Sarcoma

2017 ◽  
Author(s):  
Narasimhan P. Agaram
Keyword(s):  
Soft Tissue ◽  
Tertiary Care ◽  
Soft Tissue Sarcomas ◽  
Molecular Diagnostic ◽  
Nerve Sheath Tumor ◽  
Rare Tumors ◽  
Pathologic Evaluation ◽  
Nerve Sheath ◽  
Different Types ◽  
Tertiary Care Centers

Soft tissue sarcomas are rare tumors and are mostly managed in tertiary care centers. They are broadly classified based on their differentiation into multiple different types. They affect patients of all ages and mostly occur in the extremities. Pathologic examination of the biopsy or resection of the tumor is an extremely important aspect in the diagnosis of these tumors and appropriately guiding the clinical team in the management of these rare tumors. This review focuses on the aspects of pathologic evaluation of these tumors and discusses the morphologic aspects of the predominant soft tissue sarcomas based on differentiation. The review also highlights the latest molecular diagnostic studies that are used in the accurate subtyping of these tumors.  This review contains 12 figures, 2 tables, and 28 references. Key words: angiosarcoma, fibromatosis, fibrous, liposarcoma, myxoid, nerve sheath tumor, sarcoma, synovial sarcoma

Pathologic Evaluation of Soft Tissue Sarcoma

2017 ◽  
Author(s):  
Narasimhan P. Agaram
Keyword(s):  
Soft Tissue ◽  
Tertiary Care ◽  
Soft Tissue Sarcomas ◽  
Molecular Diagnostic ◽  
Nerve Sheath Tumor ◽  
Rare Tumors ◽  
Pathologic Evaluation ◽  
Nerve Sheath ◽  
Different Types ◽  
Tertiary Care Centers

Soft tissue sarcomas are rare tumors and are mostly managed in tertiary care centers. They are broadly classified based on their differentiation into multiple different types. They affect patients of all ages and mostly occur in the extremities. Pathologic examination of the biopsy or resection of the tumor is an extremely important aspect in the diagnosis of these tumors and appropriately guiding the clinical team in the management of these rare tumors. This review focuses on the aspects of pathologic evaluation of these tumors and discusses the morphologic aspects of the predominant soft tissue sarcomas based on differentiation. The review also highlights the latest molecular diagnostic studies that are used in the accurate subtyping of these tumors.  This review contains 12 figures, 2 tables, and 28 references. Key words: angiosarcoma, fibromatosis, fibrous, liposarcoma, myxoid, nerve sheath tumor, sarcoma, synovial sarcoma

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.

1997 ◽  
Vol 15 (6) ◽  
pp. 2378-2384 ◽  
Author(s):  
S R Patel ◽  
S Vadhan-Raj ◽  
N Papadopolous ◽  
C Plager ◽  
M A Burgess ◽  
...  
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Dose Response ◽  
Overall Response Rate ◽  
Response Rate ◽  
Soft Tissue Sarcomas ◽  
High Dose ◽  
Grade 3

PURPOSE To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas. PATIENTS AND METHODS Between July 1991 and February 1994, 74 patients with sarcomas (37 bone and 37 soft tissue) were treated on two simultaneous phase II studies that evaluated HDI given as a continuous infusion over 74 hours. G-CSF was started on day 5 at 5 microg/kg/d until recovery of granulocyte count. Additionally, between March 1993 and March 1994, 15 similar patients with previously treated bone or soft tissue sarcomas were treated on a pilot study in which the same total dose of ifosfamide was administered by a bolus schedule, along with mesna and G-CSF. Patients were treated until maximal response, and where possible, surgical resection of gross disease was performed. RESULTS Seventy-two patients from the phase II study using continuous infusion are assessable for response. Four complete responses (CRs) and 17 partial responses (PRs) were noted, for an overall response rate of 29% (95% confidence interval [CI], 19% to 39%). The response rate was 40% (95% CI, 24% to 56%) for bone sarcomas and 19% (95% CI, 6% to 32%) for soft tissue sarcomas. Fourteen patients from the pilot study that used a bolus schedule are assessable for response. One CR and seven PRs were noted, for an overall response rate of 57% (95% CI, 31% to 83%) and a response rate of 45% for soft tissue sarcomas. Two patients developed grade 3 to 4 renal toxicity, three developed grade 3 CNS toxicity, one had possible grade 3 cardiac toxicity, and two developed severe painful peripheral neuropathy. There were no treatment-related deaths. CONCLUSION HDI at 14 g/m2 with mesna and G-CSF is an active salvage regimen for patients with bone and soft tissue sarcomas. There is a definite positive dose-response curve, and bolus administration appears to be more active than continuous infusion.

Phase I Trial of Preoperative Doxorubicin-Based Concurrent Chemoradiation and Surgical Resection for Localized Extremity and Body Wall Soft Tissue Sarcomas

2004 ◽  
Vol 22 (16) ◽  
pp. 3375-3380 ◽  
Author(s):  
Peter W.T. Pisters ◽  
Shreyaskumar R. Patel ◽  
Victor G. Prieto ◽  
Peter F. Thall ◽  
Valerae O. Lewis ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase I ◽  
Continuous Infusion ◽  
Surgical Resection ◽  
Phase I Trial ◽  
Body Wall ◽  
Soft Tissue Sarcomas ◽  
Maximum Tolerated Dose ◽  
External Beam Radiation ◽  
Preoperative Radiation

Purpose The primary objective of this phase I trial was to define the maximum-tolerated dose of continuous-infusion doxorubicin administered with standard preoperative radiation for patients with localized, potentially resectable soft tissue sarcomas of the extremities or body wall. Patients and Methods Twenty-seven patients with radiographically resectable intermediate- or high-grade soft tissue sarcomas were treated. Preoperative external-beam radiation was administered in 25 2-Gy fractions (total dose, 50 Gy). Concurrent continuous-infusion doxorubicin was administered by an initial bolus (4 mg/m2) and subsequent 4-day continuous infusion (12.5, 15.0, 17.5, or 20.0 mg/m2/wk). Radiographic restaging was performed 4 to 7 weeks after chemoradiation, and patients with localized disease underwent surgical resection. Results Chemoradiation was completed as an outpatient procedure in 25 patients (93%). The maximum-tolerated dose of continuous-infusion doxorubicin combined with standard preoperative radiation was 17.5 mg/m2/wk; at this dose level, seven (30%) of 23 patients had grade 3 dermatologic toxicity. Macroscopically complete resection (R0 or R1) was performed in all 26 patients who underwent surgery. Among 22 patients who were treated with doxorubicin 17.5/mg/m2/wk with concurrent radiation and subsequent surgery, 11 patients (50%) had 90% or greater tumor necrosis, including two patients who had complete pathologic responses. Conclusion Preoperative doxorubicin-based chemoradiation appears safe and feasible. The maximum-tolerated dose of continuous-infusion doxorubicin with standard preoperative radiation was 17.5 mg/m2/wk. Pathologic response rates with this regimen are encouraging.

scholarly journals Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study

2006 ◽  
Vol 94 (12) ◽  
pp. 1797-1802 ◽  
Author(s):  
A López-Pousa ◽  
R Losa ◽  
J Martín ◽  
J Maurel ◽  
J Fra ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase I ◽  
Dose Rate ◽  
Soft Tissue Sarcomas ◽  
Fixed Dose ◽  
Fixed Dose Rate ◽  
Fixed Dose Rate Infusion ◽  
Rate Infusion

scholarly journals Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors

Sarcoma ◽  
1999 ◽  
Vol 3 (3-4) ◽  
pp. 177-181 ◽  
Author(s):  
Armando Santoro ◽  
Antonella Romanini ◽  
Alberto Rosso ◽  
Sergio Frustaci ◽  
Alessandro Comandone ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Soft Tissue Sarcomas ◽  
Rare Tumors

scholarly journals Treatment Strategies for Metastatic Soft Tissue Sarcomas

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1722
Author(s):  
Lisette M. Wiltink ◽  
Rick L. M. Haas ◽  
Hans Gelderblom ◽  
Michiel A. J. van de Sande
Keyword(s):  
Soft Tissue ◽  
Treatment Strategies ◽  
Soft Tissue Sarcomas ◽  
Molecular Characteristics ◽  
Diverse Group ◽  
Mesenchymal Origin ◽  
Rare Tumors

Soft tissue sarcomas (STS) are a diverse group of rare tumors of mesenchymal origin with different clinical, histologic and molecular characteristics [...]

Sign in / Sign up

Export Citation Format

Share Document